ARS Pharmaceuticals Inc.
SPRY | NASDAQ
$4.35
+$0.24 (+5.84%)
At close: Sep 21, 2026, 4:00 PM ET
$4.35
$0 (0.00%)
After-hours:
Sep 21, 2026, 7:30 PM ET
Market Data
Market Cap $408.14M
Enterprise Value $288.12M
Beta 0.88
Average Volume 1.94M
Shares Outstanding (Diluted) 99.31M
Shares Change YoY 0.97%
Institutional Ownership 94.77%
Exchange NASDAQ
ISIN US82835W1080
Price Performance
Price Change 1M -19.4%
Price Change 3M -57.7%
Price Change 6M -44.9%
Price Change YTD -62.1%
Price Change 1Y -55.6%
Price Change 3Y 9.8%
Price Change 5Y -58.9%
1M CAGR (ann.) -25.9%
1Y CAGR (ann.) -57.0%
5Y CAGR (ann.) -26.7%
All-Time CAGR -26.8%
Valuation
PE Ratio -2.00
Forward PE N/A
PEG Ratio 0.02
Forward PEG 0.03
PS Ratio 3.69
Forward PS 2.30
PB Ratio 34.52
P/FCF Ratio -2.20
P/Adj. FCF Ratio -1.90
P/OCF Ratio -2.20
EV/Sales 2.46
EV/EBIT -1.36
EV/EBITDA -1.38
EV/FCF -1.47
Earnings Yield -50.1%
FCF Yield -45.5%
Adj. FCF Yield -52.8%
Financial Health
Net Cash $143.85M
Total Debt $0
Cash & Short-Term Investments $143.85M
Total Assets $249.5M
Current Ratio 3.48
Quick Ratio 3.28
Debt / Equity Ratio 13.72
Debt / EBITDA -0.00
Debt / FCF -0.00
OCF / Debt N/A
Interest Coverage -43.96
Altman Z-Score -2.92
Piotroski F-Score 2
Margins & Profitability
Gross Profit Margin 73.9%
Operating Profit Margin -185.0%
EBITDA Margin -177.0%
Net Profit Margin -184.2%
FCF Margin -168.1%
Adj. FCF Margin -194.9%
SBC / Revenue 26.7%
SBC Impact (per share) -15.9%
Returns
Return on Assets -86.3%
Return on Equity -256.7%
Return on Invested Capital -114.6%
Return on Capital Employed -114.7%
Return on Tangible Assets -91.4%
Historical Growth (CAGR)
Revenue CAGR 3Y 711.3%
Revenue CAGR 5Y 94.3%
Revenue CAGR 10Y N/A
EPS CAGR 3Y -81.4%
EPS CAGR 5Y -40.2%
EPS CAGR 10Y N/A
FCF CAGR 3Y -77.7%
FCF CAGR 5Y -34.7%
FCF CAGR 10Y N/A
Analyst Forecasts
Analyst Rating Hold
Analyst Count 10
EPS Growth Next 3Y 40.4%
Revenue Growth Next 3Y 48.1%
Earnings Date N/A
EPS Estimate (next Q) N/A
EPS Growth Est (next Q) N/A
Revenue Est (next Q) N/A
Revenue Growth Est (next Q) N/A
Fair Value Estimates
Graham Number N/A
Graham Upside N/A
Lynch Fair Value N/A
Lynch Upside N/A
Price Target $20
Price Target Upside 359.8%
Cash Flow
Operating Cash Flow $-196.41M
Free Cash Flow $-196.6M
Adj. Free Cash Flow $-227.85M
FCF Per Share -$1.98
OCF Per Share -$1.98
OCF/S Ratio -168.0%
Income Statement
Revenue $116.93M
Gross Profit $86.4M
Operating Income $-216.27M
EBITDA $-209.03M
Net Income $-215.43M
EPS (Diluted) -$2.18
Revenue / Employee $599.63K
Profit / Employee $-1.1M
Employees 195
Add to Watchlist
Select watchlists to add or remove SPRY